PUBLICATION
Investigations regarding the utility of prodigiosenes to treat leukemia
- Authors
- Smithen, D.A., Forrester, A.M., Corkery, D.P., Dellaire, G., Colpitts, J., McFarland, S.A., Berman, J.N., and Thompson, A.
- ID
- ZDB-PUB-121019-37
- Date
- 2013
- Source
- Organic & biomolecular chemistry 11(1): 62-68 (Journal)
- Registered Authors
- Berman, Jason, Corkery, Dale, Forrester, Michael
- Keywords
- none
- MeSH Terms
-
- Animals
- Antineoplastic Agents/chemical synthesis
- Antineoplastic Agents/chemistry
- Antineoplastic Agents/pharmacology*
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Humans
- Leukemia/drug therapy*
- Leukemia/pathology
- Molecular Structure
- Neoplasms, Experimental/drug therapy*
- Neoplasms, Experimental/pathology
- Prodigiosin/analogs & derivatives
- Prodigiosin/chemistry
- Prodigiosin/pharmacology*
- Pyrroles/chemical synthesis
- Pyrroles/chemistry
- Pyrroles/pharmacology*
- Structure-Activity Relationship
- Zebrafish
- PubMed
- 23070266 Full text @ Org. Biomol. Chem.
Citation
Smithen, D.A., Forrester, A.M., Corkery, D.P., Dellaire, G., Colpitts, J., McFarland, S.A., Berman, J.N., and Thompson, A. (2013) Investigations regarding the utility of prodigiosenes to treat leukemia. Organic & biomolecular chemistry. 11(1):62-68.
Abstract
Prodigiosenes, possessing a 4-methoxypyrrolyldipyrrin skeleton, are known for their anti-cancer activity. Structural modification of the C-ring resulted in a series of prodigiosenes that displayed promising activity against leukemia cell lines during in vitro analysis against the NCI 60 cancer cell line panel. Further in vivo studies of these compounds using the zebrafish model showed persistence of anti-leukemia properties in human K562 chronic myelogenous leukemia cells.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping